MustGrow Biologics (TSE:MGRO)
:MGRO
Want to see TSE:MGRO full AI Analyst Report?
MGRO Stock Chart & Stats
C$0.49
C$0.01(0.67%)
At close: 4:00 PM EST
C$0.49
C$0.01(0.67%)
Day’s Range― - ―
52-Week RangeC$0.47 - C$0.94
Previous CloseN/A
Volume4.97K
Average Volume (3M)27.52K
Market Cap
C$28.54M
Enterprise ValueC$29.56M
Total Cash (Recent Filing)C$419.58K
Total Debt (Recent Filing)C$553.41K
Price to Earnings (P/E)―
Beta0.42
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.12
Shares Outstanding58,854,360
10 Day Avg. Volume43,344
30 Day Avg. Volume27,516
Financial Highlights & Ratios
PEG Ratio-0.13
Price to Book (P/B)39.49
Price to Sales (P/S)4.13
P/FCF Ratio-5.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.07
Revenue Forecast (FY)C$25.00M
Bulls Say, Bears Say
Bulls Say
Manageable LeverageDebt below equity (debt-to-equity ~0.67) means leverage is not extreme, which preserves financial flexibility over the medium term. This moderates refinancing risk and gives the company room to fund R&D or commercialization steps without immediately forcing dilutive capital raises.
Specialized Biologics Product FocusA dedicated strategy in bio-based crop protection and soil health targets structural industry demand for sustainable inputs. Specialization (mustard seed–derived technologies) supports differentiation, potential regulatory advantages, and partner interest for distribution, underpinning durable market positioning.
Historical Commercial TractionPrior revenue scale (notably 2025) demonstrates the business can commercialize products and find customers. That operational proof reduces execution risk relative to pure R&D plays and means recovery or growth is possible if product mix, go-to-market, or cost control improves.
Bears Say
Sharp Revenue DeclineA nearly 44% TTM revenue drop signals deteriorating demand or execution issues. Sustained revenue declines undermine scale economics, make fixed-cost absorption harder, and lengthen the path to profitability, increasing the need for external funding or structural changes to the business model.
Persistent Cash BurnConsistent negative operating and free cash flows indicate the company is consuming capital to run operations. Over 2–6 months this forces reliance on financing, risks dilution, constrains R&D and commercialization spend, and reduces resilience against market or regulatory setbacks.
Deep Losses And Eroded EquityVery large net losses and collapsing equity highlight structural unprofitability. Severely negative ROE and material equity erosion limit borrowing capacity, increase insolvency risk if losses continue, and create an urgent need for profitable operations or recapitalization to sustain the business long term.
MustGrow Biologics News
MGRO FAQ
What was MustGrow Biologics’s price range in the past 12 months?
MustGrow Biologics lowest stock price was C$0.47 and its highest was C$0.94 in the past 12 months.
What is MustGrow Biologics’s market cap?
MustGrow Biologics’s market cap is C$28.54M.
When is MustGrow Biologics’s upcoming earnings report date?
MustGrow Biologics’s upcoming earnings report date is Aug 20, 2026 which is in 69 days.
How were MustGrow Biologics’s earnings last quarter?
Currently, no data Available
Is MustGrow Biologics overvalued?
According to Wall Street analysts MustGrow Biologics’s price is currently Overvalued.
Does MustGrow Biologics pay dividends?
MustGrow Biologics does not currently pay dividends.
What is MustGrow Biologics’s EPS estimate?
MustGrow Biologics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does MustGrow Biologics have?
MustGrow Biologics has 58,854,360 shares outstanding.
What happened to MustGrow Biologics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of MustGrow Biologics?
Currently, no hedge funds are holding shares in TSE:MGRO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
MustGrow Biologics
MustGrow Biologics Corp. is an agricultural biotechnology enterprise specializing in the creation and commercialization of natural crop protection solutions. These offerings, including biopesticides, biofumigants, and bioherbicides, are uniquely derived from mustard seed. The company provides a pre-planting soil biofumigation technique aimed at combating soil-borne diseases and pests across diverse agricultural commodities, such as fruits and vegetables. Furthermore, MustGrow is actively developing a bioherbicide to manage undesirable plant growth, intended for use in organic farming, home gardens, and broader agricultural sectors. Their portfolio also extends to post-harvest food preservation, applying treatments to inhibit sprouting, disease, and pathogens, thereby enhancing the shelf life of stored products. A significant offering is CannaPM, an active compound effective against both fungal soil ailments and foliar diseases. Established in 2014 and headquartered in Saskatoon, Canada, the company adopted the name MustGrow Biologics Corp. in March 2018, having previously operated as Duport Capital Ltd.
MGRO Earnings Call
Q1 2026
0:00 / 0:00
Technical Analysis
Progressive Planet Solutions Inc
―
Bee Vectoring Technologies International
―
Gensource Potash
―
Verde Agritech
―
Nutrien
―
Options Prices
Currently, No data available
---